NCT01488110

Brief Summary

The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect two months post treatment. Another purpose is to investigate if and how this treatment affects manifestations of the autonomic nervous system activity.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 2, 2011

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 8, 2011

Completed
24 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
Last Updated

June 18, 2013

Status Verified

June 1, 2013

First QC Date

December 2, 2011

Last Update Submit

June 17, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in pain intensity according to VAS-scales (0-10)

    Documentation of pain intensity prior to treatment initiation (baseline value), every 5 minutes during treatment and post treatment.

    Estimation 40 minutes

Secondary Outcomes (7)

  • RR (Heart rate)-interval

    Estimation 40 minutes

  • Change from baseline in sympathetic nervous system activity

    Estimation 40 minutes

  • Blood pressure

    Estimation 40 minutes

  • Change from baseline in attack frequency based on completed patient diaries

    3 to 4 months

  • Change from baseline in attack intensity based on completed patient diaries

    3 to 4 months

  • +2 more secondary outcomes

Study Arms (2)

Migraine medical device

EXPERIMENTAL

Treatment with an active nasal probe

Device: In-house prototype invented by Jan-Erik Juto

Inactive migraine medical device

PLACEBO COMPARATOR

Treatment with an inactive nasal probe.

Device: In-house prototype invented by Jan-Erik Juto

Interventions

30 minutes treatment with an active nasal probe.

Migraine medical device

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female or male subjects, in otherwise good health, 20 to 55 years of age
  • Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
  • Subjects with a minimum of 1 migraine attack per month
  • Attack duration of 4 to 72 hours
  • Normal attack intensity of at least 4 on a 0-10 VAS-scale

You may not qualify if:

  • Completed heart surgery
  • Cardiovascular diseases
  • Vascular damages on neck vessels
  • Diseases other than migraine of the CNS
  • Severe disease of vital body organs
  • Severe psychiatric disorders
  • More than 6 migraine attacks per month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karolinska University Hospital, Huddinge

Stockholm, 14186, Sweden

Location

MeSH Terms

Conditions

Migraine Disorders

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Juto

    Karolinska University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Adjunct professor

Study Record Dates

First Submitted

December 2, 2011

First Posted

December 8, 2011

Study Start

January 1, 2012

Last Updated

June 18, 2013

Record last verified: 2013-06

Locations